Outlook Therapeutics Inc

41O

Company Profile

  • Business description

    Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.

  • Contact

    111 S. Wood Avenue
    Suite 100
    IselinNJ08852
    USA

    T: +1 609 619-3990

    E: LawrenceKenyon@outlooktherapeutics.com

    https://www.outlooktherapeutics.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    30 September 2025

    Employees

    23

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,631.5042.700.50%
CAC 407,826.791.34-0.02%
DAX 4024,226.49198.840.83%
Dow JONES (US)42,343.65740.581.78%
FTSE 1008,778.0560.080.69%
HKSE23,381.9999.660.43%
NASDAQ19,199.16461.962.47%
Nikkei 22537,724.11192.580.51%
NZX 50 Index12,531.3051.03-0.41%
S&P 5005,921.54118.722.05%
S&P/ASX 2008,407.6046.600.56%
SSE Composite Index3,340.696.15-0.18%

Market Movers